A comparison of sustained-release bupropion and placebo for smoking cessation

New England Journal of Medicine

Volumn 337, Issue 17, 1997, Pages 1195-1202

  Hurt, Richard D ^a   Sachs, David P L ^b   Glover, Elbert D ^c   Offord, Kenneth P ^a   Johnston, J Andrew ^d   Dale, Lowell C ^a   Khayrallah, Moise A ^d   Schroeder, Darrell R ^a   Glover, Penny N ^c   Sullivan, C Rollynn ^c   Croghan, Ivana T ^a   Sullivan, Pamela M ^c  

^a MAYO CLINIC   (United States)

^b Palo Alto Center for Pulmonary Disease Prevention   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE;

ADULT; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SMOKING CESSATION; SUSTAINED RELEASE PREPARATION; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DELAYED-ACTION PREPARATIONS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER; WEIGHT GAIN;

EID: 0030720886     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199710233371703     Document Type: Article

References (36)

1. Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9.
2. Hall SM, Munoz R, Reus V. Smoking cessation, depression and dysphoria. NIDA Res Monogr 1991;105:312-3.
3. Glass RM. Blue mood, blackened lungs: depression and smoking. JAMA 1990;264:1583-4.
4. Hughes JR. Dependence potential and abuse liability of nicotine replacement therapies. In: Pomerleau O, Pomerleau C, eds. Progress in clinical evaluation. New York: Alan R. Liss, 1988:261-77.
5. Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry 1990;31:350-4.
6. Hall SM, Munoz RF, Reus VI. Cognitive-behavioral intervention increases abstinence rates for depressive-history smokers. J Consult Clin Psychol 1994;62:141-6.
7. Shiffman S. Relapse following smoking cessation: a situational analysis. J Consult Clin Psychol 1982;50:71-86.
8. Edwards NB, Murphy JK, Downs AD, Ackerman BJ, Rosenthal TL. Doxepin as an adjunct to smoking cessation: a double-blind pilot study. Am J Psychiatry 1989;146:373-6.
9. Sellers EM, Naranjo C, Kadlec K. Do serotonin uptake inhibitors decrease smoking? Observations in a group of heavy drinkers. J Clin Psychopharmacol 1987;7:417-20.
10. Ferry LH, Burchette RJ. Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Dis 1994;13:249.
11. Spitzer RL, Williams JBW, Gibbon M, First MB. User's guide for the structured clinical interview for DSM-III-R: SCID. Washington, D.C.: American Psychiatric Press, 1990.
12. Glynn TJ, Manley MW. How to help your patients stop smoking: a National Cancer Institute manual for physicians. Bethesda, Md.: National Cancer Institute, 1990. (NIH publication no. 90-3064.)
13. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986;43:289-94.
14. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav 1978;3:235-41.
15. Beck AT, Steer RA. Beck Depression Inventory. Philadelphia: Center for Cognitive Therapy, 1978.
16. Swenson WM, Morse RM. The use of a self-administered alcoholism screening test (SAAST) in a medical center. Mayo Clin Proc 1975;50:204-8.
17. Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989;12: 159-82.
18. Ferris RM, Cooper BR. Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monogr 1993;11:2-14.
19. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: a meta-analysis. JAMA 1994;271: 1940-7.
20. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991;324:739-45.
21. Klesges RC, Somes GW, Pascale R, et al. Knowledge and beliefs regarding the consequences of cigarette smoking and their relationships to smoking status in a biracial sample. Health Psychol 1988;7:387-401.
22. Tønnesen P, Fryd V, Hansen M, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. N Engl J Med 1988;318:15-8.
23. Nides M, Rand C, Dolce J, et al. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol 1994;13:354-61.
24. Leischow SJ, Sachs DPL, Bostrom AG, Hansen MD. Effects of differing nicotine-replacement doses on weight gain after smoking cessation. Arch Fam Med 1992;1:233-7.
25. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multicenter controlled clinical trials. JAMA 1991;266:3133-8.
26. Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med 1993;153:1881-90. [Erratum, Arch Intern Med 1993;153:2321.]
27. Sutherland G, Stapleton JA, Russell MA, et al. Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992; 340:324-9.
28. Perkins KA. Issues in the prevention of weight gain after smoking cessation. Ann Behav Med 1994;16:46-52.
29. Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1988.
30. Wise RA. Brain neuronal systems mediating reward processes. In: Smith JE, Lane JD, eds. Neurobiology of opiate reward mechanisms. New York: Elsevier Biomedical Press, 1983:405-38.
31. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-8.
32. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382:255-7.
33. Clarke PB. Nicotine dependence - mechanisms and therapeutic strategies. Biochem Soc Symp 1993;59:83-95.
34. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
35. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50:256-61.
36. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52: 450-6.